ASDs
The Evolving Science of Amorphous Solid Dispersions
Pharma's Almanac
PAO-10-26-PA-13Oct 20, 2026
OpenAI Funding
OpenAI Foundation: The Why and How of Its Life Science Research Funding Agenda
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-26-PA-12Oct 19, 2026
Liver Cancer
Overcoming Resistance in the New Era of Liver Cancer Immunotherapy
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-26-PA-11Oct 16, 2026
CLD
Can Mammalian Cell-Line Engineering Become a High-Throughput Design Problem?
Pharma's Almanac
PAO-10-26-PA-09Oct 14, 2026
Formulation Models
Predictive Formulation: Can Modeling Reduce Empirical Development?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-26-PA-04Oct 7, 2026
Viral Vectors
Gene Therapy Manufacturing After the Capacity Boom
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-26-PA-01Oct 1, 2026
New Technology
What are the key bottlenecks preventing rapid adoption of novel technologies?
Pharma's Almanac
PAO-09-26-RT-01Sep 30, 2026
Heme-Onc
Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-09-26-PA-20Sep 28, 2026
Heme-Onc
The Next Generation of Targeted Therapies in Hematologic Malignancies
PAO-09-26-PA-11Sep 24, 2026
AMT Designation
AustinPx’s KinetiSol™ Technology Receives FDA Advanced Manufacturing Technology Designation
AustinPx
PR-09-26-04Sep 23, 2026
DDC Development
Building Better Combination Products by Engaging Device Development Earlier
Loganathan S.
OneSource Specialty Pharma
PAO-09-26-CL-05Sep 22, 2026
Allogeneic CAR-T
Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?
Pharma's Almanac
PAO-09-26-PA-14Sep 18, 2026
BsAbs in Oncology
Bispecific Antibodies Move Into the Heme-Onc Mainstream
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-12Sep 16, 2026
Pediatric Oncology
Why Pediatric Oncology Needs Its Own Drug Development Paradigm
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-04Sep 4, 2026
Development CDMO
The Case for Earlier CDMO Involvement in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-02Sep 2, 2026
MPS
What Will It Take for Organ-on-Chip Data to Replace Animal Studies?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-18Aug 31, 2026
Chinese Biopharma
Pharmaceutical Innovation in China Takes Center Stage
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-17Aug 25, 2026
Potency Assurance
Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-16Aug 24, 2026
Preparedness
Preparing Manufacturing Networks for the Next Pandemic
Pharma's Almanac
PAO-08-26-PA-14Aug 20, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13Aug 18, 2026